VRG Technologies, Inc.


 Home Up Products Patents Investing Press Releases Contacts

  Gene Therapy


Vector Research - Global Technologies.


Gene therapy comprises technologies through which defective or missing genetic information is corrected by inserting new genetic information into the cell. The genetic information may be in the form of genes, portions of genes, DNA, ribonucleic acid (RNA), nucleic acids, or oligonucleotides. This may be carried out ex vivo (that is, cells are removed from the patient, genetically modified, and then reinfused), or in vivo (new genetic material is delivered to cells inside the patient’s body). Antisense oligonucleotides, catalytic ribozymes, and genes corresponding to proteins are the major products currently available in gene therapy. The applications, in theory, of gene therapy include: correcting inherited gene disorders engineering immunity against viral diseases and cancer developing vaccines and intracellular immunization therapies regulating cardiovascular and metabolic diseases and delivery drugs and “suicide” cells.

According to a soon-to-be-released Business Communications Company, Inc. study, RC-160R: Human Gene Therapy: Technology Analysis and Market Forecast, the first gene therapy is expected to reach the U.S. market by 2000 and is projected to exceed $2 billion in 2002. The first therapies to enter the market most likely will be the treatment for glioblastoma now in Phase III trials under the sponsorship of Genetic Therapy/Novartis; Introgen/RPR Gencell’s treatment for nonsmall cell lung cancer, which is just entering Phase II/III trials; Isis’ antisense treatment for AIDS-related cytomegalovirus (CMV) retinitis; and/or a treatment of Gaucher disease.

BCC believes that of the estimated $12 billion market for gene therapy products projected for the year 2007, over 80% of revenues will be derived from products to treat cancer. The remaining revenues will come from treatments for viral diseases, specifically human immunodeficiency virus (HIV infection); treatments for anemia; treatments for monogenic disorders, specifically cystic fibrosis, familial hypercholesterolemia, Gaucher disease, and hemophilias; and treatments for other selected disorders, including arterial restenosis.

After 2010, treatments for more complex or multiple-gene-defect diseases such as Alzheimer’s disease and diabetes will enter the market. The gene therapy market for diabetes alone is projected to exceed $5 billion, treatments for cardiovascular diseases could generate another $5 billion or more, and gene therapy for Alzheimer’s could generate up to $10 billion.

($ Millions)

Product Category 1997 2002 2007 AAGR% 1997-2007
Monogenic Diseases Cystic Fibrosis /TD> 0 42 145 --
Gaucher Disease 0 2.5 10 --
Cancer 0 3,560 9,935 --
HIV/AIDS 0 120 780 --
Other Diseases Anemias 0 0 450 --
Arterial Restenosis 0 0 600 --

Source: Business Communications Company, Inc.

C-160R Human Gene Therapy: Technology Analysis and Market Forecast

PUBLISHED: January 1998

Data and analysis provided courtesy of BUSINESS COMMUNICATIONS COMPANY, INC., 25 Van Zant Street, Norwalk, CT 06855,  Telephone: (203) 853-4266; ext. 309,  Email: publisher@bccresearch.com

Back Home Up Next 


VRG Technologies, Inc.

Last Modified : 12/10/01 07:09 PM

Copyright 2001